GlobeNewswire

Cisco Tetration Workload Protection Extended with New Options: SaaS and Virtual Appliance

Dela

New Tetration models deliver faster deployment and pay-as-you-grow flexibility

 

SAN JOSE, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- Cisco today announced two new consumption models for its Cisco® Tetration solution for the data center and cloud: Tetration SaaS, the cloud-based solution for cloud-first and cloud-only organizations, and Tetration-V, a software-only version using a virtual appliance for smaller deployments. Both models deliver the same features and functionality as the original on-premises form factors of Tetration. Tetration automates application dependency mapping and whitelist policy generation and enforcement, gives insight into network performance, and offers cloud workload protection. The Tetration  APIs enable IT organizations to create custom applications with access to Tetration data sources, allowing the export and enforcement of policies generated by Tetration across SDN controllers and security devices.

With the new consumption models, organizations can adopt Tetration technology within hours, with no initial investment and the flexibility to pay as they grow.

With Tetration SaaS, organizations gain the benefits of a fully managed model, including:

  • Workload protection features without any on-premises hardware requirements
  • Protection for on-premises, public, and private cloud workloads
  • Scalability up to 25,000 workloads
  • Data retention for months
  • Faster onboarding to realize the benefits of the platform quickly
  • Built-in high availability and disaster recovery capability
  • Service backed by world-class SLAs
  • Managed services provided by Cisco channel partners

For organizations that deploy fewer than 1000 workloads and prefer a software-only approach, Tetration is available on a virtual appliance. It offers one-click deployment and allows organizations to use their own server and storage infrastructure. 

Both Tetration models deliver a ready-to-use solution to identify data center applications, their detailed dependencies, and the underlying policies between different application tiers. Operators can implement a zero-trust model using whitelist policy and segmentation, monitor the behavior of server processes, and identify software-related vulnerabilities. Tetration is able to identify high-severity security events such as certain Spectre and Meltdown exploits using behavior-based anomalies, allowing proactive quarantining of affected servers. With this approach, Tetration provides holistic cloud workload protection anywhere. For more information, see A Recipe to Keep Your Hybrid Cloud Workloads Safe.

"Cisco Tetration helps Xentaurs manage successful cloud and data center deployments for our clients by ensuring every single connection and flow to an application is visible," said Anoj Willy, CEO, Xentaurs. "Without this critical information, app, cloud, and data center migrations would be impossible to precisely guarantee nothing is missed and everything is as it is intended. Tetration goes further in establishing and enforcing a zero-trust environment that is the foundation for microsegmentation, down to containers and next-generation services development."

Cisco's architectural approach to security 
Tetration is also a core technology in Cisco's data center security and workload protection portfolio. Tetration works with Cisco ACI and Cisco's security portfolio, including Cisco Firepower® Next-Generation Firewall (NGFW), Next-Generation IPS (NGIPS), Advanced Malware Protection (AMP), and Stealthwatch® to deliver effective security that follows the workload everywhere. Now operators can see everything across their network, reduce the attack surface, and stop data center breaches from moving laterally across workloads.  For more information, see Redefining Security for the Modern Data Center in a Multi-Cloud World.

Cisco Services for Tetration
If requested, Cisco can also provide professional and support services for Tetration SaaS and Tetration-V, including: support for Tetration onboarding and use-case support to accelerate Tetration adoption and optimize policies and security, resulting in a faster time to value with Tetration.  

Availability
Cisco Tetration SaaS is scheduled to be available in May 2018. Tetration-V is available now. 

Additional resources   
Learn more about Cisco TetrationLearn more about Cisco ACI(TM)
Learn more about Cisco ACI ecosystem partnersLearn more about Cisco data center technologyLearn more about Services for Cisco Tetration

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at thenetwork.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.

RSS Feed for Cisco: http://newsroom.cisco.com/rss-feeds

Press Relations: 
Lee Davis   
Cisco 
650-868-3036
leedavis@cisco.com             
Analyst Relations:
Aimee Schoaf 
Cisco 
623-377-0377
aschoaf@cisco.com             
Investor Relations:
Carol Villazon
Cisco
408-527-6538
carolv@cisco.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum